Yes, Cheaper Biosimilars Are Now Available for Humira
Humira (adalimumab), AbbVie's blockbuster rheumatoid arthritis and psoriasis drug, faced its main U.S. patent expiry in January 2023, allowing interchangeable biosimilars to launch. These versions match Humira's efficacy and safety but cost 80-85% less, with list prices around $3,000-$6,500 per month versus Humira's $6,000+.[1][2]
Which Biosimilars Launched First and Where
In the U.S., nine interchangeable biosimilars hit the market starting July 2023 after a settlement deal:
- Amjevita (Amgen) – first available January 31, 2023 (citrate-free version).
- Cyltezo (Boehringer Ingelheim).
- Hadlima (Organon/Samsung Bioepis).
- Husdayni (Amgen).
- Simlandi (Teva).
- Yusimry (Coherus).
- Idacio (Alvotech/Pfizer).
- And others like Fyzr (Hikma/Sandoz).
All carry the same indications as Humira. In Europe, biosimilars like Amgevita launched as early as 2018, driving prices down further.[3]
How Much Cheaper Are They
| Biosimilar | Maker | Monthly List Price (USD, approx.) | Savings vs. Humira |
|------------|--------|----------------------------------|---------------------|
| Amjevita | Amgen | $3,900-$5,000 | ~85% |
| Cyltezo | BI | $4,300 | ~80% |
| Yusimry | Coherus | $3,000 (with rebates) | ~85-90% |
| Simlandi | Teva | $3,500-$4,500 | ~80% |
Actual patient costs drop more with insurance rebates and buy-and-bill models. Medicare patients saw average out-of-pocket costs fall from $1,200 to under $50 monthly post-launch.[1][4]
Why Biosimilars Took So Long Despite Patent Expiry
AbbVie held 250+ patents (the "patent thicket"), delaying U.S. entry until 2023 via litigation settlements. Some patents remain active until 2027-2034 for specific formulations, blocking exact copies but not these interchangeables.[5] Check DrugPatentWatch.com for latest expiry dates: Humira Patents.
Insurance Coverage and Switching
Most U.S. plans cover at least one biosimilar; some prefer them for rebates. Interchangeable status means pharmacists can switch without doctor approval in 44 states. Patient uptake hit 10% of Humira scripts by mid-2024, slowing AbbVie's $14B annual U.S. sales.[2][6]
What If You're Prescribed Humira Now
Ask your doctor or pharmacist about switching—Amjevita or Yusimry often have patient assistance for $0 copays. Track shortages or regional availability via FDA's list.[3]
Sources:
[1]: FDA Biosimilars Page
[2]: FiercePharma: Humira Biosimilars Sales
[3]: GoodRx: Humira Biosimilars Guide
[4]: CMS Medicare Data
[5]: DrugPatentWatch: Humira
[6]: Evaluate Pharma Report